Barrons Medical
Journa Reporting From John Hopkins University Campus Baltimore Maryland
Scientist at GenNXeix Biotech Is Predicting There Is Going To Be A Breast Cancer Cure Before The End of President Obama 2nd Term:
Barron's Medical Journal Year End Report
Baltimore Maryland ( AP) Did you know that we have a breast cancer treatment model that has not changed in many Physicians offices since 1970? In 1970 A MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian woman. MCF-7 is the acronym of Michigan Cancer Foundation - 7, referring to the institute in Detroit where the cell line was established in 1973 by Herbert Soule and co-workers The Michigan Cancer Foundation is now known as the Barbara Ann Karmanos Cancer Institute.
This is why we now have analytics that says that fifty percent of the Women in the United States that get chemotherapy do not need it. This is why that so many reports says that Black women get breast cancer and a rate of 18% and White women a rate of 7% .
Prior to MCF-7, it was not possible for cancer researchers to obtain a mammary cell line that was capable of living
longer than a few months, since the 1950’s when this car was created a big change in the way we treat breast cancer patients in 1970… Now In 2012 we are making another major change. The Change is a Medical Technology Called Genomics.
The patient, whose name, Frances Mallon, is unknown to the vast majority of cancer researchers, died in 1970. Her cells were the source of much of current knowledge about breast cancer
Scientist around world is working with genomics. For an example, The International Cancer Genome Consortium (ICGC) today announced four new projects in China to identify the genomic drivers in colorectal, esophageal, liver and nasopharyngeal cancers, helping lay the foundation for developing treatments tailored to patients’ individual needs. China is a founding member of the ICGC, having launched a gastric cancer project in 2008.
Brought To You By gloStream
The Consortium leads worldwide efforts to map the genomes of both common and rare cancers and has the goal of identifying cancer-causing mutations in more than 25,000 tumors representing more than 50 types of cancer of clinical and societal importance across the globe.
Houston base companies like Gennxeix Biotech found involvement in human breast cancer progression, based on the analysis of human breast cancer biopsies and experimental animal mice models. HIF-1 as a therapeutic target can extend the life of many stage four breast Cancer patients.
Gennxeix discovered The tumor suppressors VHL (von Hippel-Lindau protein) and p53 target HIF-1α for ubiquitination to inactivation breast cancer tumors cells increases the of HIF-1. This process Increased phosphatidylinositol 3-kinase (PI3K) and AKT. In breast cancer, increased activity of the HER2 (also known as neu) receptor tyrosine kinase is associated with increased tumor grade, chemotherapy resistance, and decreased patient survival. HER2 has also been implicated as an inducer of VEGF expression. GenNXeix demonstrate that HER2 signaling induced by overexpression in mouse 3T3 cells or human MCF-7 breast cancer cells results in increased HIF-1α protein and VEGF mRNA expression that is dependent upon activity of PI3K, AKT (also known as protein kinase B), and the downstream kinase FRAP (FKBP-rapamycin-associated protein)
Gennxeix concern with patients with diabetes and breast cancer may not receive full Benefit of HIF-1. All women having access to a physician can have access to HIF-1.
Genomics provide a faster cheaper more effective way to detecting Breast Cancer by using Semiconductor Sequencing.
A example of this technique is Gennxeix Semiconductor Sequencing.
"Quantum Theory" In Action for Breast Cancer Patients.
A polymerase is an enzyme whose central function is associated with polymers of nucleic acids such as RNA and DNA. The primary function of a polymerase is the polymerization of new DNA or RNA against an existing DNA or RNA template in the processes of replication and transcription. In association with a Gennxeix also uses a Visualize Real-Time Breast Cancer Data using Signal Stochastic Resonance Units Neurons Detection
and Analysis for Breast Cancer model after McCulloch-Pitts.
Gennxeix. computer-assisted diagnosing of breast cancer from mammograms. Gennxeix works is a genetic network simulation trained with tumor incidence data from knockout experiments.
Gennxeix uses Semiconductor Sequencing Chips that create a direct connection between Biochemical and digital information, bringing these two languages together. Gennxeix's chips are designed like any other semiconductor chips.
Pairing proprietary semiconductor technology with sequencing
chemistry a nucleotide is incorporated into a strand of DNA by a polymerase, a hydrogen ion is released.
Gennxeix used a high-density array of micro-machined wells for bioctechnology process in a massive way. Each well holds a different DNA template. Beneath the wells is an ion-sensitive layer and beneath that a proprietary Ion sensor.
Genomics can be the GPS to Extend life in Breast Cancer Patients.
Brought To You By Antiques of River Oaks Houston,Tx
Barron's Medical Journal reports that hope for young women, those under 35, who get breast cancer out of the blue – especially because they are far more likely than older women to have a hard-to-treat type of breast cancer called triple negative breast cancer. A chemotherapy treatment called neoadjuvant chemotherapy can actual reduce the size of large triple negative breast cancer tumors. The efficacy of neoadjuvant chemotherapy, as measured by the rate of pathological complete response (the absence of invasive and intraductal disease in the breast and the axillary lymph nodes), varies according to breast-cancer subtype. When anthracyclines, taxanes, and agents directed against anti–human. First degree relatives of Breast Cancer Patients that take a Genomic test and find that the genes P53, P63, Her-2 and more are the largest candidates neoadjuvant chemotherapy
treatments. A Houston base company called Gennxeix researcher work product. lets discuss some of their finding. Gennxeix discovered that some patients with HER2-positive breast cancer tended not respond to HER2-targeted therapies. Also, some patients with triple-negative breast cancers responded to therapies while others didn't. "We have been lumping things together that shouldn't be lumped together The new classifications - four types called HER2 "enriched," luminal A, luminal B and basal-like - categorize breast cancers by their genomic structure using a dizzying array of data points not previously available that have identified new pathways for the cancer to do its damage, making it possible for researchers to identify new places to target disease. Brought To You By Antiques of River Oaks Houston,Tx In what could be seen as the most promising development of this breast cancer study, researchers determined that some basal-like cancers had more in common with an aggressive form of ovarian cancer known as "serous" than with other types of breast cancer.
In late December 2012 we are on the door step of a breast cancer cure. Scientist at GenNXeix Biotech is predicting that there is going to be a breast cancer before the end of the 2nd Term of President Obama.
